Chaixin Injection Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied as a bulk active pharmaceutical ingredient for formulation into the seven listed dosage routes. The designation “Injection Grade” establishes that the release specification includes bacterial endotoxin, sub-visible particle, and bioburden controls appropriate to parenteral processing; it does not mean the material is supplied sterile. The product model is the manufacturer’s campaign-specific grade designation and must be read from the certificate of analysis and batch packaging record. The route categories in the trade name identify downstream dosage forms, not a single finished formulation. Processing must occur in GMP-licensed veterinary drug-product facilities under the applicable marketing authorisation and target-species safety file.

The material is controlled by two interdependent specification sets. Physical specifications include particle-size distribution by laser diffraction (ISO 13320:2020), bulk density and tapped density (USP <616>; Ph. Eur. 2.9.34), loss on drying or water content by Karl Fischer titration (USP <921> Method Ia), and powder flow by shear cell or angle of repose (USP <1174>). Chemical and microbiological specifications include related substances by HPLC (USP <621>), residual solvents (USP <467>; VICH GL18), elemental impurities (USP <232>; USP <233>; ICH Q3D), bacterial endotoxins (USP <85>; Ph. Eur. 2.6.14), and where a sterile claim is qualified, sterility (USP <71>; Ph. Eur. 2.6.1).

Intended use is as a raw material for registered veterinary medicinal products across the seven listed dosage routes. Direct administration is contraindicated. The API must be formulated, tested, and released by a GMP-licensed manufacturer. In food-producing animals, residue depletion studies and withdrawal periods are established at the finished-product level, not by the API alone. Use in non-target species requires a veterinary prescription and residue assessment under the applicable regional residue control framework.

For solid oral processing, flowability is typically expressed as Hausner ratio and compressibility index. A Hausner ratio below 1.25 is generally considered free-flowing; values above 1.40 are classified as cohesive. Published data for this exact Chaixin API’s shear-cell flow function is limited, so the supplier’s certificate of analysis should be evaluated against the intended unit-operation train. On rotary tablet presses operating at 60–80 rpm, die-fill variability becomes measurable when the material’s angle of repose exceeds 40° or when moisture uptake under ambient relative humidity above 60% exceeds the registered limit. If incoming loss on drying is above 1.0% w/w, pre-drying in a fluid-bed dryer at 40–50 °C for 2–4 h is required before direct compression or encapsulation, provided the active’s thermal stability allows that cycle.

The active pharmaceutical ingredient should also be characterised for solid-state form by X-ray powder diffraction and differential scanning calorimetry. If the molecule is polymorphic, the injection-grade material must be assigned to a specific polymorphic form because dissolution rate and suspension physical stability depend on crystal habit and specific surface area. Thermal gravimetric analysis defines desolvation and decomposition thresholds, which set the maximum drying temperature for pre-drying operations. The CoA should include residue on ignition (USP <281>), and specific surface area by nitrogen adsorption (USP <846>) when the intended dosage form is a lyophilised cake or microsuspension.

What physical controls govern granulation and parenteral suspension uniformity?

Wet high-shear granulation of the API for tablet and granule dosage forms is performed in equipment with impeller tip speeds between 5 m/s and 10 m/s. A final wet-mass moisture target of 1.5–3.0% w/w is common before fluid-bed drying to a loss-on-drying endpoint of ≤ 1.0% w/w. The dried granule is screened through an oscillating granulator fitted with a 0.8–1.25 mm screen, and sieve analysis (USP <786>; Ph. Eur. 2.9.12) confirms that not less than 85% w/w is retained between 125 µm and 1000 µm for feed-premix uniformity. Direct compression and capsule filling require a narrower particle-size range to avoid segregation; a D50 between 75 µm and 250 µm is often targeted for dry blends, while a finer D50 of ≤ 30 µm may be required if the injection is a suspension rather than a solution. These values are route-specific and must be justified by process validation data; they are not universal for every active moiety.

If direct compression is not feasible, roller compaction is used with a roll force of 5–15 kN/cm and roll speed 5–15 rpm to densify the powder into ribbons. The ribbon is milled to a granule size distribution suitable for encapsulation or tableting. Roller compaction preserves low moisture and avoids an aqueous granulation step that could hydrolyse the active. The compacted granules should have a bulk density in the range 0.45–0.75 g/cm³ for reliable die filling. Below that range, flowability can be insufficient; above it, tablet tensile strength may decline because of reduced particle compressibility. These ranges are common industrial setup points, not a registered limit for this Chaixin grade.

For capsules and tablets, dissolution is not an API release parameter but a finished-product parameter. However, particle-size distribution and polymorphic purity directly affect dissolution rate. In formulation screening, intrinsic dissolution rate is measured by rotating-disk compendial apparatus (USP <1087>) at 100 rpm in a specified dissolution medium. Lot-to-lot variability in intrinsic dissolution rate above 10% RSD at 15 min indicates a need for particle-size or polymorph control. Published data for this exact Chaixin API’s intrinsic dissolution rate is limited, so finished-product dissolution method and acceptance criteria must be developed under VICH GL1 and VICH GL2.

Parenteral liquid manufacture from this API is governed by chemical purity plus low endotoxin and extraneous particulate controls. For solutions, the active is dissolved in water for injection or an approved co-solvent, then passed through a sterilising-grade 0.22 µm membrane filter under pressure-controlled conditions. The filter is typically polyethersulfone or polyvinylidene fluoride, selected after extractables screening. Terminal sterilisation may be substituted if the active is thermostable; an autoclave cycle of 121 °C for 15 min or equivalent F₀ ≥ 8 min is used only after thermal-degradation studies demonstrate that related substances remain within registered limits. Lyophilised injections are dried to a final moisture content of ≤ 1.0% w/w by Karl Fischer titration to maintain cake structure and reconstitution time.

For lyophilised injectables, the API solution is freeze-dried in cycles with shelf temperatures from −40 °C to +25 °C and chamber pressures between 5 Pa and 20 Pa. The resulting cake is tested for moisture, sterility, and reconstitution time. The injection-grade API must have a low initial bioburden and low endotoxin concentration because lyophilisation does not remove endotoxin and cannot correct a contaminated API. Aseptic filling is conducted under Grade A conditions per EU GMP Annex 1:2022.

Solution stability is evaluated by forced degradation in acidic, neutral, and alkaline buffers, typically pH 2, pH 7, and pH 10, with oxidative stress at 3% H₂O₂. These studies are designed under VICH GL5 photostability and long-term stability protocols under VICH GL3. If the active shows pH-dependent hydrolysis, the registered formulation must fix buffer strength and pH at the lower-tolerance edge of the degradation plateau. Published data for this exact Chaixin API’s pH-rate profile is limited and must be supplied by the manufacturer.

When oral premix, capsule, and injection specifications are consolidated in a single API grade

Consolidating seven dosage-form routes into one injection-grade API differs from single-grade veterinary APIs in three distinct control domains. First, the parenteral limit for bacterial endotoxins is the controlling specification for all batch routing; an oral-only batch cannot be released with a higher endotoxin burden merely because it is destined for granules or premix. Second, particle-size optimisation is not universal. A fine API that passes injectable suspension dispersibility may be too cohesive for direct-compression tablet production, requiring wet granulation or roller compaction with a subsequent sieving step. Third, residual solvent and elemental impurity limits follow the most stringent route. Class 1 solvents are controlled under VICH GL18 and USP <467>; Class 2 solvents such as dichloromethane and methanol are limited by route-specific permitted daily exposure values, with parenteral PDEs lower than oral feed PDEs. A single-grade API therefore carries the strictest limits across all routes.

Compared with oral-only API, the Chaixin injection grade carries a lower bioburden ceiling and is manufactured with closed-system transfer to reduce extraneous particulate and microbial ingress. Compared with injectable-only API, it is additionally characterised for powder flow, sieve profile, and blend uniformity to support solid dosage form processing. Single-route APIs may be optimised for one unit operation, but a multi-route grade accepts specification overhead on every batch. The operational consequence is that parenteral limits on endotoxin and sub-visible particulate matter are imposed even on batches ultimately used for premix; this increases analytical workload but reduces the risk of misrouted inventory.

Endotoxin, residual solvent, and sub-visible particulate control points

Bacterial endotoxin testing is performed by limulus amebocyte lysate assay according to USP <85> or Ph. Eur. 2.6.14. The limit is product-specific and must be derived from the maximum intended parenteral dose. Sub-visible particulate matter is assessed after final solution preparation by light obscuration particle counting under USP <788> or Ph. Eur. 2.9.19. For small-volume injections, the limits are generally 6000 particles per container at ≥ 10 µm and 600 particles per container at ≥ 25 µm, but the applicable finished-product monograph controls the final acceptance criterion. Residual solvents are controlled by headspace gas chromatography under VICH GL18 and USP <467>. If a batch is directed to injectable use, the strictest parenteral PDE applies; the same batch cannot later be reclassified to oral-only use without documented disposition and quality-unit approval.

Prefiltration and sterilising filtration are not neutral operations. A fine-particle API may bind to polyethersulfone or nylon membranes, and solution pH or surfactant content may affect recovery. Filter compatibility studies are performed at 0.22 µm and 0.45 µm pore sizes with product-wetted membrane disks; the filtrate is assayed for active content and related substances after a simulated batch hold time. If active loss exceeds 2% or an impurity increases by more than 0.10%, the membrane polymer or prefilter design must be changed. Published data for this exact Chaixin API–membrane interaction is limited, so the manufacturing site must perform site-specific validation.

Batch-to-batch variability on production-scale equipment is a critical control point. When the API is milled through a conical mill with round-hole screens of 0.5 mm or 1.0 mm, particle-size distribution can shift by 5–10% between campaigns if the mill rotor speed or feed rate is not fixed. The manufacturing record should specify mill type, screen size, rotor speed, and throughput. Failure to fix these parameters has been observed to increase tablet weight variability from below 2% RSD to above 4% RSD on high-speed rotary presses. This operational boundary is not product-specific to Chaixin but is applicable to multi-route veterinary APIs.

In a production-scale bin blender of 600 L working capacity, low-dose premix uniformity is checked by sampling at 10 predefined positions and comparing assay values against the target potency. Blend uniformity is evaluated under USP <905> for finished dosage units and in-process validation protocols for medicated feed premix. If the API’s D50 is below 20 µm and the carrier particle size is above 800 µm, stratification risk increases; a sieved carrier granulometry with a controlled particle-size ratio is recommended to reduce segregation during silo discharge and bagging. For capsules, powder fill weight is controlled by tamping-pin or dosator settings, and the API’s bulk density should be held within a narrow campaign range to avoid fill-weight drift.

Incompatibility screening with common veterinary excipients—lactose monohydrate, microcrystalline cellulose, pregelatinised starch, and calcium hydrogen phosphate dihydrate—must be completed before bulk blending. The API should not be dry-mixed with oxidising agents or exposed to high-humidity open handling for more than the qualified hold time. At relative humidity above 60%, pre-drying and humidity-controlled suites are required to avoid lot-to-lot moisture drift. For liquid preparations, the final solution pH should be maintained within the ranges defined by forced-degradation data; excursions below pH 2 or above pH 10 may accelerate hydrolysis or oxidative degradation in a molecule-specific manner, so the registered formulation must not be extrapolated between active salts or polymorphs without new stability data.